PARP1 and cancer: Given the tantalizing preclinical and early clinical activity of PARP inhibitors in HR-deficient tumors, there has also been substantial interest in inducing a state of temporary HR deficiency in hopes of sensitizing cancers that lack inactivating mutations in the Fanconi anemia (FA)/HR pathway.